NCT06168487

Telmisartan in Prostate Cancer

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Tyler J Curiel · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.

Detailed description

The primary objective of this study is to test the tolerability of oral telmisartan given as a single agent or combined with specific standard of care agents in selected participants with PC. Patients will be defined as tolerating telmisartan if they maintain systolic blood pressure \>110 mm Hg and are without greater than grade 2 toxicities as defined in the Common Terminology Criteria for Adverse Events v5.1 for at least 60 days total telmisartan treatment.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Telmisartan	Patients will be given telmisartan alone or with standard of care chemotherapy.
OTHER	Standard of Care Regimen	Standard of Care Regimen

Timeline

• Start date: 2024-04-22
• Primary completion: 2026-04-01
• Completion: 2027-04-01
• First posted: 2023-12-13
• Last updated: 2025-08-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study